Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development.

Wold EA, Wild CT, Cunningham KA, Zhou J.

Curr Top Med Chem. 2019;19(16):1381-1398. doi: 10.2174/1568026619666190709101449. Review.

2.

Resistance to Second-Generation HIV-1 Maturation Inhibitors.

Urano E, Timilsina U, Kaplan JA, Ablan S, Ghimire D, Pham P, Kuruppu N, Mandt R, Durell SR, Nitz TJ, Martin DE, Wild CT, Gaur R, Freed EO.

J Virol. 2019 Mar 5;93(6). pii: e02017-18. doi: 10.1128/JVI.02017-18. Print 2019 Mar 15.

3.

Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor.

Wild CT, Miszkiel JM, Wold EA, Soto CA, Ding C, Hartley RM, White MA, Anastasio NC, Cunningham KA, Zhou J.

J Med Chem. 2019 Jan 10;62(1):288-305. doi: 10.1021/acs.jmedchem.8b00401. Epub 2018 Apr 13.

4.

Identification of potent maturation inhibitors against HIV-1 clade C.

Timilsina U, Ghimire D, Timalsina B, Nitz TJ, Wild CT, Freed EO, Gaur R.

Sci Rep. 2016 Jun 6;6:27403. doi: 10.1038/srep27403.

5.

Functionalized N,N-Diphenylamines as Potent and Selective EPAC2 Inhibitors.

Wild CT, Zhu Y, Na Y, Mei F, Ynalvez MA, Chen H, Cheng X, Zhou J.

ACS Med Chem Lett. 2016 Mar 28;7(5):460-4. doi: 10.1021/acsmedchemlett.5b00477. eCollection 2016 May 12.

6.

Is it time to define minimally clinically important differences for patient-reported outcome measures used in alcohol brief intervention studies?

Newton AS, Wild CT.

Addiction. 2016 Sep;111(9):1528-9. doi: 10.1111/add.13184. Epub 2016 Mar 6. No abstract available.

PMID:
26948288
7.

Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.

Urano E, Ablan SD, Mandt R, Pauly GT, Sigano DM, Schneider JP, Martin DE, Nitz TJ, Wild CT, Freed EO.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):190-7. doi: 10.1128/AAC.02121-15. Print 2016 Jan.

8.

A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat.

Lu W, Salzwedel K, Wang D, Chakravarty S, Freed EO, Wild CT, Li F.

Antimicrob Agents Chemother. 2011 Jul;55(7):3324-9. doi: 10.1128/AAC.01435-10. Epub 2011 Apr 18.

9.

Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation.

Yunus AS, Jackson TP, Crisafi K, Burimski I, Kilgore NR, Zoumplis D, Allaway GP, Wild CT, Salzwedel K.

Virology. 2010 Jan 20;396(2):226-37. doi: 10.1016/j.virol.2009.10.040. Epub 2009 Nov 18.

10.

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.

Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE.

PLoS One. 2007 Nov 28;2(11):e1251.

11.

In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).

Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO.

J Virol. 2006 Nov;80(22):10957-71. Epub 2006 Sep 6.

12.

Determinants of activity of the HIV-1 maturation inhibitor PA-457.

Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT.

Virology. 2006 Dec 5-20;356(1-2):217-24. Epub 2006 Aug 22.

13.

3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro.

Sakalian M, McMurtrey CP, Deeg FJ, Maloy CW, Li F, Wild CT, Salzwedel K.

J Virol. 2006 Jun;80(12):5716-22.

14.

The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV.

Yu D, Wild CT, Martin DE, Morris-Natschke SL, Chen CH, Allaway GP, Lee KH.

Expert Opin Investig Drugs. 2005 Jun;14(6):681-93. Review.

PMID:
16004596
15.

Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection.

Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM.

J Exp Med. 2004 Nov 15;200(10):1337-46.

16.

3-O-Glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents.

Kashiwada Y, Sekiya M, Ikeshiro Y, Fujioka T, Kilgore NR, Wild CT, Allaway GP, Lee KH.

Bioorg Med Chem Lett. 2004 Dec 6;14(23):5851-3.

PMID:
15501054
17.

PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.

Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT.

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60. Epub 2003 Oct 22.

18.

History and measurement of continuity of care in mental health services and evidence of its role in outcomes.

Adair CE, McDougall GM, Beckie A, Joyce A, Mitton C, Wild CT, Gordon A, Costigan N.

Psychiatr Serv. 2003 Oct;54(10):1351-6.

PMID:
14557520
19.
21.

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR, Stamatatos L.

J Virol. 2001 Jun;75(12):5526-40.

22.

Capture of an early fusion-active conformation of HIV-1 gp41.

Furuta RA, Wild CT, Weng Y, Weiss CD.

Nat Struct Biol. 1998 Apr;5(4):276-9. Erratum in: Nat Struct Biol 1998 Jul;5(7):612.

PMID:
9546217
24.

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ.

Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4.

Supplemental Content

Support Center